Cytiva

Overview

Cytiva is a Danaher bioprocessing company spanning monoclonal antibodies, viral vectors, and cell therapy. Cytiva's bioprocess technologies enabled monoclonal antibody therapies to reach over 30 million patients, nearly 95% of all patients treated with these modalities in 2025. Cytiva works across monoclonal antibodies, viral vectors, and cell therapy spanning the development, analytical, and release bottlenecks that shape patient access.